BWXT Stock Analysis: BWX Technologies | NYSE
Aerospace & Defense | NYSE, USA | Market Cap: 11.515m USD | 12M Return: -36.6% | US05605H1005 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 157M
EPS Trend: 99.0%
Qual. Beats: 12
Rev. Trend: 98.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
BWX Technologies, Inc. (NYSE: BWXT) is a U.S.-based manufacturer of nuclear components operating through two segments: Government Operations and Commercial Operations. Its offerings include naval nuclear reactors and fuel, precision components for defense applications, commercial nuclear steam generators, pressure vessels, heat exchangers, fuel handling systems, and containers for spent nuclear fuel storage. The company also produces medical radioisotopes, radiopharmaceuticals, and medical devices, and provides specialized engineering services spanning thermal-hydraulic analysis, metallurgy, non-destructive examination, in-plant inspection, and full nuclear power plant lifecycle support.
The company is classified in the Industrials sector under the Aerospace & Defense sub-industry, a placement driven primarily by its role as a domestic supplier of proprietary, sole-source components for naval nuclear propulsion programs. Originally founded in 1867 as Babcock & Wilcox and rebranded BWX Technologies in June 2015, the company is headquartered in Lynchburg, Virginia, and serves government and commercial customers across the United States, Canada, and select international markets.
- Naval nuclear reactor components win multi-year defense contracts
- Microreactor development gains DoD and DOE funding support
- Commercial nuclear fuel backlog grows on utility restart demand
- Medical isotope production expands to new radiopharmaceutical customers
- Discretionary pension de-risking frees up capital for buybacks
| Net Income: 374.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -4.41 > 1.0 |
| NWC/Revenue: 23.35% < 20% (prev 14.96%; Δ 8.39% < -1%) |
| CFO/TA 0.12 > 3% & CFO 578.7m > Net Income 374.9m |
| Net Debt (1.45b) to EBITDA (573.8m): 2.53 < 3 |
| Current Ratio: 1.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.0m) vs 12m ago 0.22% < -2% |
| Gross Margin: 22.58% > 18% (prev 23.54%; Δ -0.95% > 0.5%) |
| Asset Turnover: 84.39% > 50% (prev 80.89%; Δ 3.50% > 0%) |
| Interest Coverage Ratio: 17.61 > 6 (EBIT TTM 450.4m / Interest Expense TTM 25.6m) |
| A: 0.18 (Total Current Assets 1.80b - Total Current Liabilities 960.9m) / Total Assets 4.75b |
| B: 0.57 (Retained Earnings 2.73b / Total Assets 4.75b) |
| C: 0.11 (EBIT TTM 450.4m / Avg Total Assets 4.27b) |
| D: 0.43 (Book Value of Equity 1.42b / Total Liabilities 3.34b) |
| Altman-Z'' = 4.19 = AA |
| DSRI: 0.33 (Receivables 352.0m/915.6m, Revenue 3.60b/3.06b) |
| GMI: 1.04 (GM 23.54% / 22.58%) |
| AQI: 1.18 (AQ_t 0.35 / AQ_t-1 0.30) |
| SGI: 1.18 (Revenue 3.60b / 3.06b) |
| TATA: -0.04 (NI 374.9m - CFO 578.7m) / TA 4.75b) |
| Beneish M = -3.32 (Cap -4..+1) = AA |
As of November 13, 2026, the stock is trading at USD 123.99 with a total of 720,303 shares traded. Over the past week, the price has changed by +7.85%, over one month by -11.39%, over three months by -28.03% and over the past year by -36.63%.
Current recommended Stop Loss: 116.60 (which is 6% or 1.2 ATR below the current price).
BWX Technologies has received a consensus analysts rating of 4.39. Therefore, it is recommended to buy BWXT.
- StrongBuy: 11
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 202.3 | 63.2% |
P/E Trailing = 30.8796
P/E Forward = 22.6244
P/S = 3.1982
P/B = 8.1809
P/EG = 1.6728
Revenue TTM = 3.60b USD
EBIT TTM = 450.4m USD
EBITDA TTM = 573.8m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last fiscal year)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.45b USD (calculated: Debt 2.02b - CCE 568.5m)
Enterprise Value = 13.0b USD (11.5b + Debt 2.02b - CCE 568.5m)
Interest Coverage Ratio = 17.61 (Ebit TTM 450.4m / Interest Expense TTM 25.6m)
EV/FCF = 34.83x (Enterprise Value 13.0b / FCF TTM 372.3m)
FCF Yield = 2.87% (FCF TTM 372.3m / Enterprise Value 13.0b)
FCF Margin = 10.34% (FCF TTM 372.3m / Revenue TTM 3.60b)
Net Margin = 10.41% (Net Income TTM 374.9m / Revenue TTM 3.60b)
Gross Margin = 22.58% ((Revenue TTM 3.60b - Cost of Revenue TTM 2.79b) / Revenue TTM)
Gross Margin QoQ = 23.84% (prev 22.44%)
Tobins Q-Ratio = 2.73 (Enterprise Value 13.0b / Total Assets 4.75b)
Interest Expense / Debt = 1.27% (Interest Expense 25.6m / Debt 2.02b)
Taxrate = 17.15% (77.8m / 453.8m)
NOPAT = 373.1m (EBIT 450.4m * (1 - 17.15%))
Current Ratio = 1.88 (Total Current Assets 1.80b / Total Current Liabilities 960.9m)
Debt / Equity = 1.43 (Debt 2.02b / totalStockholderEquity, last quarter 1.42b)
Debt / EBITDA = 2.53 (Net Debt 1.45b / EBITDA 573.8m)
Debt / FCF = 3.90 (Net Debt 1.45b / FCF TTM 372.3m)
Total Stockholder Equity = 1.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.78% (Net Income 374.9m / Total Assets 4.75b)
RoE = 28.48% (Net Income TTM 374.9m / Total Stockholder Equity 1.32b)
RoCE = 13.49% (EBIT 450.4m / Capital Employed (Equity 1.32b + L.T.Debt 2.02b))
RoIC = 10.30% (NOPAT 373.1m / Invested Capital 3.62b)
WACC = 8.33% (E(11.5b)/V(13.5b) * Re(9.61%) + D(2.02b)/V(13.5b) * Rd(1.27%) * (1-Tc(0.17)))
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.64 | Cagr: 0.09%
[DCF] Terminal Value 73.10% ; FCFF base≈408.5m ; Y1≈358.3m ; Y5≈289.5m
[DCF] Fair Price = 34.85 (EV 4.65b - Net Debt 1.45b = Equity 3.19b / Shares 91.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 98.95 | EPS CAGR: 15.70% | SUE: 1.11 | # QB: 12
Revenue Correlation: 98.36 | Revenue CAGR: 15.16% | SUE: -0.84 | # QB: -1
EPS current Quarter (2027-03-31): EPS=1.16 | Chg30d=-1.20% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=4.76 | Chg30d=+0.32% | Revisions=-25% | GrowthEPS=+18.6% | GrowthRev=+18.5%
EPS next Year (2027-12-31): EPS=5.22 | Chg30d=-0.12% | Revisions=-25% | GrowthEPS=+9.7% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: -36% (up=3, down=8)